Format

Send to

Choose Destination
Expert Opin Biol Ther. 2008 Jun;8(6):713-7. doi: 10.1517/14712598.8.6.713 .

Estrogen and MYB in breast cancer: potential for new therapies.

Author information

1
Professorial Research Fellow, Deputy Director and Head Cancer Biology Program, University of Queensland Diamantina Institute for Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. t.gonda@uq.edu.au

Abstract

MYB is highly expressed in almost all estrogen receptor (ER)-positive breast tumours and is a direct target of estrogen/ER signalling. Our recent studies have shown that MYB is also required for the proliferation of ER-positive breast tumour cell lines, and have shed further light on the mechanism of ER regulation of MYB expression. Here we discuss the rationale for therapeutic targeting of MYB in breast cancer and consider a number of approaches to developing an anti-MYB therapeutic.

PMID:
18476782
DOI:
10.1517/14712598.8.6.713
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center